>>SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Corgentech Inc. (Nasdaq: CGTK - News) will host a webcast teleconference Monday, December 6, 2004 at 8:30 a.m. Eastern Time to review top-line results from PREVENT III, a Phase 3 clinical trial testing edifoligide (E2F Decoy) for the treatment of peripheral artery bypass graft failure.
Interested parties can listen to the live audio webcast, or the subsequent archived recording, by logging on to www.corgentech.com and going to the Investor Information page. Please connect to Corgentech's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by calling 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 2693369.
About Corgentech
Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, and cancer. For more information on the company and its technology, visit www.corgentech.com. <<
Darn! I was hoping to snag some January options early next week, as I didn't pull the trigger earlier this week. Looks like I missed my shot. By my Mom's holding a little, so hoping for the best.
Cheers, Tuck |
